Oyster Point begins enrolment for Phase 3 ONSET-2 study of nasal spray
Category: #health  By Mateen Dalal  Date: 2019-07-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oyster Point begins enrolment for Phase 3 ONSET-2 study of nasal spray

The trial is designed to assess the efficacy and safety of OC-01 for treating dry eye disease

Reports confirm that Oyster Point Pharma, a clinical-stage biopharmaceutical company, has recently announced that the first subject has been enrolled in the Phase 3 ONSET-2 clinical study of OC-01 Nasal Spray to treat the symptoms and signs of dry eye disease.

According to CEO and President of Oyster Point Pharma, Jeffrey Nau, Ph.D., M.M.S., after successfully completing the registrational Phase 2b clinical study i.e. ONSET-1, the company has announced the commencement of the second registrational trial, ONSET-2.

It is believed that OC-01 has the potential to change the method used by eye care physicians to treat patients with dry eye disease, owing to the fast onset of action in surging natural tear film production, the capability to substantially improve both symptoms and signs of dry eye disease, and a promising tolerability profile.

The innovative delivery of OC-01 as a nasal spray spares the ocular surface and allows the product’s novel mechanism of action, offering unique benefits to patients and eye care practitioners.

Reportedly, the ONSET-2 clinical trial is a double-masked, randomized, multicentre, placebo-controlled clinical study to assess the efficacy and safety of OC-01 nasal spray for treating the symptoms and signs of dry eye disease.

The study, which will recruit around 750 subjects at around 20 U.S. centers, will investigate two dosages of OC-01 nasal spray, 1.2 mg/ml, and 0.6mg/ml, as compared to placebo nasal spray. The pre-specified primary endpoint of the clinical trial will be the evaluation of tear production as calculated by the percentage of subjects showing a 10 mm or bigger change at week 4 from baseline Schirmer’s Score.

A member of medical advisory board of Oyster Point Pharma and an ophthalmologist at Virginia Eye Consultants, Elizabeth Yeu, M.D., stated that it is inspiring to view the progress Oyster Point is achieving in the development of OC-01. There is a substantial requirement for therapeutic options that can successfully benefit a wide population of patients with dry eye disease.

 

Source Credits: https://oysterpointrx.com/oyster-point-pharma-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...